| Neoadjuvant and Adjuvant Therapy Studies of Sintilimab Combined With Chemotherapy With or Without Ipilimumab N01 in Resectable Gastric/Gastroesophageal Junction Adenocarcinoma (NCT07643623) | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | 2026-07-31 |
| Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid Tumors (NCT07589205) | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | 2026-03-31 |
| A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment. (NCT07490262) | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | 2026-03-27 |
| IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (NCT07377643) | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | 2026-02-10 |
| A Study of Picankibart in Patients With Active Psoriatic Arthritis (NCT07295509) | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | 2025-12-18 |
| A Study to Evaluate Efficacy and Safety of IBI112 in Adolescent Participants With Moderate to Severe Plaque Psoriasis (NCT07265284) | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | 2025-12-03 |
| A Study of Switching to Picankibart in Chinese Patients With Plaque Psoriasis With an Inadequate Response to Interleukin-17 Monoclonal Antibody Therapy (NCT06945107) | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | 2025-05-27 |
| Study of IBI3020 Treatment in Participants With Late-Stage Solid Tumors (NCT06963281) | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | 2025-04-29 |